Skip to Content

Trintellix Approval History

Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).

On May 2, 2016, Takeda Pharmaceuticals U.S.A., Inc. announced that Brintellix (vortioxetine) will be marketed under the new name Trintellix (vortioxetine) effective June 2016. The name change comes after reports of name confusion in the marketplace between Brintellix and the anti-blood clotting therapy Brilinta (ticagrelor).

Development History and FDA Approval Process for Trintellix

May  2, 2016Approval Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
Sep 30, 2013Approval FDA Approves Brintellix to Treat Major Depressive Disorder
Dec 12, 2012FDA Accepts Takeda and Lundbeck's Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
Oct  1, 2012Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for the Treatment of Major Depressive Disorder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.